HINT2 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for studying HINT2 function. This loss-of-function model was generated by CRISPR/Cas9-mediated gene disruption in the HAP1 cell line, resulting in a heterogeneous population of cells with disrupted HINT2 alleles. The polyclonal format retains genetic diversity while enabling robust assessment of HINT2-dependent phenotypes in a near-haploid background.
The HAP1 cell line is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line. HAP1 cells grow adherently and carry a male karyotype with a single copy of most chromosomes, including chromosome 2 where HINT2 resides, thereby simplifying gene knockout and phenotypic analysis. The haploid nature reduces genetic redundancy, making HAP1 an advantageous host for loss-of-function studies, particularly for genes involved in apoptosis and cancer.
HINT2 encodes a mitochondrial phosphoramidase that functions as a pro-apoptotic factor downstream of p53. Upon activation by p53, DNA damage, or oxidative stress, HINT2 promotes mitochondrial membrane permeabilization through interactions with the adenine nucleotide translocator and mitochondrial contact site components. This facilitates BAX/BAK oligomerization, cytochrome c release, and subsequent caspase-9 and effector caspase activation, culminating in apoptosis. In cancer, HINT2 is frequently silenced, suggesting a tumor suppressor role, especially in hepatocellular carcinoma and colorectal cancer.
In the HAP1 background, HINT2 disruption allows direct interrogation of its mitochondrial apoptotic function without interference from a wild-type allele. This polyclonal knockout pool is suitable for comparing apoptotic responses, mitochondrial integrity, and drug sensitivity between HINT2-null and HINT2-expressing HAP1 cells. For example, researchers can investigate how loss of HINT2 affects cisplatin-induced apoptosis or resistance, providing insights into chemotherapeutic mechanisms.
Typical applications include Western blotting and RT-qPCR to confirm HINT2 loss, Annexin V/PI staining and JC-1 assays to measure apoptosis and mitochondrial membrane potential, and caspase activity assays to dissect signaling. The model supports drug sensitivity profiling, co-culture experiments, and genetic rescue studies. Together, these HINT2 Knockout HAP1 Polyclonal Cells offer a versatile platform for cancer biology and mitochondrial disorder research. For additional technical information, please contact Ascent Research.
